title: The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas.
abstract: OBJECTIVE
  To document the long-term prognosis of patients with non-Hodgkin lymphoma treated between 1971 and 1975 and to determine how the prognosis varies by histologic subtype and stage.
  
  
  METHODS
  Three cancer referral centers in the United States and one center in Italy.
  
  
  METHODS
  A consecutive sample of 1153 previously untreated patients with non-Hodgkin lymphoma. At the time of analysis, 71% of the patients had died and the median follow-up for patients still alive was 11.2 years.
  
  
  RESULTS
  The 10-year survival proportions were 45% (CI, 40% to 50%); 26% (CI, 22% to 30%); and 23% (CI, 18% to 30%) for patients with low-, intermediate-, and high-grade lymphomas, respectively. Patients with intermediate- and high-grade lymphomas were curable, but this was not apparent for patients with advanced stage low-grade lymphomas. For the low-grade follicular small cleaved and follicular mixed lymphomas, the Ann Arbor staging system distinguished the prognosis of patients with stage I disease from those with more extensive involvement. For the diffuse large cell and immunoblastic lymphomas, the Ann Arbor staging system distinguished long-term prognosis for patients with stage I disease from patients with stage II disease and those with more disseminated involvement.
  
  
  CONCLUSIONS
  The probability of long-term survival for unselected patients with non-Hodgkin lymphoma can be substantial. Long-term prognosis depends on the histologic subtype of the tumor and the extent of dissemination. The Working Formulation for non-Hodgkin lymphomas is a simple and useful nomenclature for selecting treatment and reporting results. The Ann Arbor staging system is a useful but imperfect prognostic indicator.
authors.affiliation: University of Minnesota, Minneapolis.
authors.forename: R
authors.initials: R
authors.lastname: Simon
authors.forename: S
authors.initials: S
authors.lastname: Durrleman
authors.forename: R T
authors.initials: RT
authors.lastname: Hoppe
authors.forename: G
authors.initials: G
authors.lastname: Bonadonna
authors.forename: C D
authors.initials: CD
authors.lastname: Bloomfield
authors.forename: R A
authors.initials: RA
authors.lastname: Rudders
authors.forename: B D
authors.initials: BD
authors.lastname: Cheson
authors.forename: C W
authors.initials: CW
authors.lastname: Berard
mesh_terms: D001853:Bone Marrow / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000145:classification* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D011379:Prognosis